LGP2: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 30: | Line 30: | ||
[[Category:Immune system]] | [[Category:Immune system]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 17:50, 17 March 2025
LGP2 (Laboratory of Genetics and Physiology 2) is a protein that in humans is encoded by the DHX58 gene. It is a part of the RIG-I-like receptor (RLR) signaling pathway, which is a crucial component of the innate immune response to viral infections.
Function[edit]
LGP2 is a member of the DExD/H box family of RNA helicases. It acts as a negative regulator of the RLR pathway by preventing the interaction of MAVS (Mitochondrial Antiviral-Signaling protein) with RIG-I and MDA5, two other key proteins in the pathway. This regulation is essential for preventing excessive immune responses that could lead to harmful inflammation.
Clinical significance[edit]
Alterations in the function of LGP2 have been associated with a variety of diseases. For example, mutations in the DHX58 gene have been linked to increased susceptibility to viral infections. Additionally, dysregulation of the RLR pathway, in which LGP2 plays a key role, has been implicated in autoimmune diseases such as Systemic lupus erythematosus and Rheumatoid arthritis.
See also[edit]
- RIG-I-like receptor
- Innate immune response
- RNA helicase
- MAVS
- Systemic lupus erythematosus
- Rheumatoid arthritis
References[edit]
<references />


